Characteristics of included (PCR-verified SARS-CoV-2 infection) individuals by CLL status
| Variable . | CLL (n = 1289) . | No CLL (n = 2 086 874) . |
|---|---|---|
| Age, median (IQI), y | 75.0 (66.0-82.0) | 43.0 (31.0-55.0) |
| Age category, y, n (%) | ||
| ≤39 | 2 (0.2) | 900 776 (43.2) |
| 40-49 | 25 (1.9) | 444 167 (21.3) |
| 50-59 | 145 (11.2) | 373 164 (17.9) |
| 60-69 | 271 (21.0) | 189 714 (9.1) |
| 70-79 | 426 (33.0) | 95 892 (4.6) |
| ≥80 | 420 (32.6) | 83 161 (4.0) |
| Male sex, n (%) | 844 (65.5) | 962 863 (46.1) |
| Region of birth, n (%) | ||
| Sweden | 1075 (83.4) | 1 613 953 (77.3) |
| Outside Sweden | 214 (16.6) | 472 694 (22.7) |
| Missing | 0 | 227 (0.0) |
| Income quartile, n (%) | ||
| 1 | 414 (32.1) | 528 062 (25.3) |
| 2 | 398 (30.9) | 514 511 (24.7) |
| 3 | 173 (13.4) | 512 839 (24.6) |
| 4 | 234 (18.2) | 520 426 (24.9) |
| Missing | 70 (5.4) | 11 036 (0.5) |
| Prescription drug use, n (%) | ||
| Anticoagulant | 571 (44.3) | 167 379 (8.0) |
| Antidiabetic | 260 (20.2) | 105 115 (5.0) |
| Antihypertensive | 797 (61.8) | 358 682 (17.2) |
| Heart disease drug | 108 (8.4) | 41 722 (2.0) |
| Immunosuppressive drug | 321 (24.9) | 42 678 (2.0) |
| Lipid modifier | 446 (34.6) | 171 087 (8.2) |
| Obstructive lung disease drug | 211 (16.4) | 182 877 (8.8) |
| CLL treatments, n (%) | ||
| BCL-2i | 70 (5.4) | NA |
| BTKi | 239 (18.5) | NA |
| PI3Ki | 7 (0.5) | NA |
| Corticosteroids | 139 (10.8) | NA |
| Any of the above treatments | 368 (28.5) | NA |
| Time from CLL diagnosis to PCR test, n (%) | ||
| During SARS-CoV-2 infection | 73 (5.7) | NA |
| <1 year | 127 (9.9) | NA |
| 1-5 years | 456 (35.4) | NA |
| >5 years | 633 (49.1) | NA |
| COVID-19 vaccination status 14 days before first infection, n (%) | ||
| Unvaccinated | 381 (29.6) | 1 088 607 (52.2) |
| 1 dose | 29 (2.2) | 48 498 (2.3) |
| 2 doses | 133 (10.3) | 645 648 (30.9) |
| 3 doses | 435 (33.7) | 251 709 (12.1) |
| 4 doses | 202 (15.7) | 33 429 (1.6) |
| 5 doses | 109 (8.5) | 18 983 (0.9) |
| SARS-CoV-2 variant, n (%) | ||
| Wild type | 258 (20.0) | 551 711 (26.4) |
| Alpha | 122 (9.5) | 389 996 (18.7) |
| Beta | 1 (0.1) | 2441 (0.1) |
| Gamma | 0 | 189 (0.0) |
| Delta | 73 (5.7) | 141 316 (6.8) |
| Omicron | 835 (64.8) | 1 001 221 (48.0) |
| Variable . | CLL (n = 1289) . | No CLL (n = 2 086 874) . |
|---|---|---|
| Age, median (IQI), y | 75.0 (66.0-82.0) | 43.0 (31.0-55.0) |
| Age category, y, n (%) | ||
| ≤39 | 2 (0.2) | 900 776 (43.2) |
| 40-49 | 25 (1.9) | 444 167 (21.3) |
| 50-59 | 145 (11.2) | 373 164 (17.9) |
| 60-69 | 271 (21.0) | 189 714 (9.1) |
| 70-79 | 426 (33.0) | 95 892 (4.6) |
| ≥80 | 420 (32.6) | 83 161 (4.0) |
| Male sex, n (%) | 844 (65.5) | 962 863 (46.1) |
| Region of birth, n (%) | ||
| Sweden | 1075 (83.4) | 1 613 953 (77.3) |
| Outside Sweden | 214 (16.6) | 472 694 (22.7) |
| Missing | 0 | 227 (0.0) |
| Income quartile, n (%) | ||
| 1 | 414 (32.1) | 528 062 (25.3) |
| 2 | 398 (30.9) | 514 511 (24.7) |
| 3 | 173 (13.4) | 512 839 (24.6) |
| 4 | 234 (18.2) | 520 426 (24.9) |
| Missing | 70 (5.4) | 11 036 (0.5) |
| Prescription drug use, n (%) | ||
| Anticoagulant | 571 (44.3) | 167 379 (8.0) |
| Antidiabetic | 260 (20.2) | 105 115 (5.0) |
| Antihypertensive | 797 (61.8) | 358 682 (17.2) |
| Heart disease drug | 108 (8.4) | 41 722 (2.0) |
| Immunosuppressive drug | 321 (24.9) | 42 678 (2.0) |
| Lipid modifier | 446 (34.6) | 171 087 (8.2) |
| Obstructive lung disease drug | 211 (16.4) | 182 877 (8.8) |
| CLL treatments, n (%) | ||
| BCL-2i | 70 (5.4) | NA |
| BTKi | 239 (18.5) | NA |
| PI3Ki | 7 (0.5) | NA |
| Corticosteroids | 139 (10.8) | NA |
| Any of the above treatments | 368 (28.5) | NA |
| Time from CLL diagnosis to PCR test, n (%) | ||
| During SARS-CoV-2 infection | 73 (5.7) | NA |
| <1 year | 127 (9.9) | NA |
| 1-5 years | 456 (35.4) | NA |
| >5 years | 633 (49.1) | NA |
| COVID-19 vaccination status 14 days before first infection, n (%) | ||
| Unvaccinated | 381 (29.6) | 1 088 607 (52.2) |
| 1 dose | 29 (2.2) | 48 498 (2.3) |
| 2 doses | 133 (10.3) | 645 648 (30.9) |
| 3 doses | 435 (33.7) | 251 709 (12.1) |
| 4 doses | 202 (15.7) | 33 429 (1.6) |
| 5 doses | 109 (8.5) | 18 983 (0.9) |
| SARS-CoV-2 variant, n (%) | ||
| Wild type | 258 (20.0) | 551 711 (26.4) |
| Alpha | 122 (9.5) | 389 996 (18.7) |
| Beta | 1 (0.1) | 2441 (0.1) |
| Gamma | 0 | 189 (0.0) |
| Delta | 73 (5.7) | 141 316 (6.8) |
| Omicron | 835 (64.8) | 1 001 221 (48.0) |
NA, not applicable.